Routine kidney screening belongs in primary care, not at the edge of specialty care
Chronic kidney disease rarely announces itself, but it steadily compounds clinical risk and cost. The disease is tightly linked to heart disease, diabetes, and obesity, which means kidney decline seldom behaves like an isolated organ problem; it travels with the broader cardiometabolic burden that primary care already manages every day. Treating late-stage kidney failure consumes far more resources than treating early disease, and dialysis alone can become financially overwhelming before hospitalizations, lost productivity, and caregiver burden are even counted.
The gap is not a lack of biologic plausibility or therapeutic options. It is a failure of routine detection.
Nearly 90% of U.S. adults have at least one cardiovascular-kidney-metabolic, or CKM, risk factor, yet most people with CKD do not know they have it. In practical terms, that means the disease often advances far enough to alter treatment decisions, referral patterns, and long-term cost trajectories before a clinician ever has a chance to intervene. For primary care, routine screening is not an optional add-on. It is the point where prevention can still work.
CKM disease reframes kidney risk as a shared cardiometabolic process
The American Heart Association introduced CKM disease in its 2023 presidential advisory to describe how cardiovascular disease, CKD, and metabolic disorders interact in the body. Rather than treating these as separate silos, the framework stages risk from 0 through 4, with later stages reflecting established cardiovascular disease and often kidney failure. The value of that model is clinical coherence: one abnormal system accelerates the others, and a single missed diagnosis can reverberate across all three.
The scale of the problem is larger than many practices appreciate. CKD affects roughly 14% of U.S. adults, or an estimated 37 million people, and most remain unaware of the condition. Globally, nearly 800 million adults live with CKD, more than double the 378 million recorded in 1990. The age-standardized prevalence is approximately 14% worldwide, and the disease is becoming a more significant driver of cardiovascular mortality.
Kidney disease now ranks as the ninth-leading cause of death globally, claiming close to 1.5 million lives a year. The biology is familiar to clinicians, but the public health consequence is still underappreciated: CKD does not wait for symptoms, and the health system often waits for symptoms before testing.
eGFR and urine albumin together catch disease that either test can miss
Routine screening hinges on two measures: estimated glomerular filtration rate, or eGFR, typically drawn from a basic metabolic panel, and urine albumin-to-creatinine ratio, or UACR. Together, they provide a far more complete picture of kidney risk than either test alone. Blood pressure, glucose, and lipid data add to the risk assessment, but eGFR and UACR remain the core tests for identifying CKD early and staging CKM risk more accurately.
The 2024 KDIGO guideline reinforces that approach, recommending assessment with both GFR and urine albumin measurements in people at risk for chronic kidney disease. The reason is straightforward: kidney injury can be present even when serum creatinine looks reassuring, and albuminuria can reveal disease activity before filtration decline becomes obvious.
A screening program across 16 sites in Cameroon made the point sharply. When both tests were used, blood testing alone would have missed 85% of the kidney disease cases identified by urine testing. In routine primary care, where eGFR is often ordered without UACR, a substantial share of disease remains invisible.
Silent progression keeps patients out of treatment until options narrow
Kidney disease progresses quietly because function can decline substantially before a patient feels unwell. By the time fatigue, edema, or other symptoms appear, a patient may already have crossed into a stage where intervention is more complex and more expensive. This is why routine screening matters more than symptom-driven testing.
In Bermuda, about 49% of screened participants had abnormal results, and 94% of those people did not know they had the condition. In Cameroon, nearly half of almost 35,000 people screened had abnormal UACR results, and nearly 1,000 needed immediate nephrology referral. Those findings describe a disease burden that is already well established by the time a patient reaches care. They also show how quickly clinic-based screening can uncover patients who would otherwise remain undiagnosed.
The downstream consequences are expensive. As kidney disease advances, costs climb steeply, and treatment becomes more dependent on access to specialty care and dialysis infrastructure. In places where nephrology access is limited, patients may face hours of travel for referral visits. Rural communities in the United States face a similar problem when the nearest specialist is tied to a distant hospital system.
Primary care now carries more of the kidney workload by necessity
Nephrology faces a workforce bottleneck. The Association of American Medical Colleges has projected a shortage of up to 77,100 specialists nationally by 2034, and nephrology fellowship programs have struggled to fill positions. That shortage is already affecting care pathways. In one academic health system study, only 45.4% of patients with an eGFR under 30 who were seeing a primary care physician were referred, despite guideline thresholds that should prompt nephrology involvement.
Primary care cannot replace nephrology, but it can identify who truly needs referral and who can be managed safely in the office setting. Blood pressure control, glycemic management, and kidney-protective medications such as RAAS inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists are already within primary care scope for many patients with early or moderate disease. The right referral strategy keeps scarce specialty appointments for the patients most likely to need them.
That is a better use of both time and expertise.
GLP-1 therapy now carries dedicated kidney-outcomes evidence
GLP-1 receptor agonists were first developed for glycemic control, but their cardiorenal effects have become increasingly important in practice. The strongest kidney-specific evidence in the article comes from the FLOW trial, which tested semaglutide in more than 3,500 patients with type 2 diabetes and existing CKD. The trial stopped early for efficacy. Semaglutide reduced the primary composite outcome of major kidney events, cardiovascular death, and death from any cause by 24%, and it slowed the rate of eGFR decline compared with placebo.
For clinicians, that matters because the argument for GLP-1 therapy in a patient with type 2 diabetes and CKD no longer rests only on weight loss or glucose lowering. The kidney outcome data now support a direct organ-protective role in the population studied. The evidence does not yet extend to all patients with CKD, especially those without diabetes, so treatment conversations still need to stay anchored to the actual trial population.
The article also points to broader class effects. Semaglutide at a higher dose has reduced body weight by up to 15% and lowered the risk of major cardiovascular events by 20% in people with obesity but without diabetes, while newer multihormone agents such as tirzepatide have produced weight loss of up to 22.5% in phase 3 trials. Those results strengthen the biologic case that metabolic therapies can influence multiple organs at once, but the dedicated kidney-outcomes evidence remains strongest for semaglutide in type 2 diabetes with CKD.
Tracking trends over time helps primary care act before the next referral crisis
A single lab value is only a snapshot. Repeated eGFR and UACR measurements show whether a patient is stable, drifting, or deteriorating. Monitoring tools that track those trends can help primary care distinguish between slow progression and urgent decline, and that difference affects whether a patient needs immediate nephrology input or close office-based follow-up.
The experience in Bermuda is a concrete example of what screening data can trigger. The results were strong enough to support a national CKD Integrated Care Pathway, building coordinated follow-up infrastructure around the screening findings. That is the kind of system-level response primary care needs: a way to translate testing into action, not just diagnosis.
For large health systems, the financial case is especially stark. One U.S. claims analysis found annual costs rising from roughly $7,500 with no kidney disease to nearly $77,000 at stage 4 or 5. Early detection prevents that escalation by shifting care earlier, when medication adjustment, monitoring, and referral can still alter the course of disease. Small and independent practices may not control the payment model, but they do control whether CKD screening becomes part of routine preventive care or remains an afterthought until advanced disease arrives.